Scholarlink

Background <p>Mediator complex subunit 8 (MED8) is the main regulator of RNA polymerase. Its expression is associated with a poor prognosis and tumor immune features in many tumors, but the role of <i>MED8</i> in gliomas is unknown.</p> Methods <p>In this study, bioinformatics analysis was used to explore the effect of <i>MED8</i> in gliomas and the correlation between <i>MED8</i> and tumor immune features and the response to immunotherapy in gliomas. The expression of <i>MED8</i> in cell lines was studied by qPCR.</p> Results <p>Studies show increased expression of <i>MED8</i> is associated with poor prognosis in glioma. Cox regression analysis and survival analysis revealed that <i>MED8</i> is an independent prognostic factor in gliomas, and patients with high expression of <i>MED8</i> have a poor prognosis. Functional analysis revealed that there was a close relationship between <i>MED8</i> expression and tumor immune features, and there was a correlation between <i>MED8</i> expression and tumor-associated macrophages (TAMs) levels. In addition, glioma patients with low expression of <i>MED8</i> were more sensitive to anti-PD-1/anti-CTLA4 immunotherapy, while patients with high expression of <i>MED8</i> were more sensitive to temozolomide (TMZ).</p> Conclusion <p>These results show that <i>MED8</i> is a marker of prognosis and immunotherapy/chemotherapy response in glioma and a target of anti-TAMs immunotherapy for glioma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MED8 is related to tumor immunity and has predictive value in the prognosis and treatment of glioma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月28日

查看全文
  • Jingyi Yang,
  • Bin Li,
  • Xinghai Zhang,
  • Yufeng Li,
  • Hao Yuan

摘要

Background

Mediator complex subunit 8 (MED8) is the main regulator of RNA polymerase. Its expression is associated with a poor prognosis and tumor immune features in many tumors, but the role of MED8 in gliomas is unknown.

Methods

In this study, bioinformatics analysis was used to explore the effect of MED8 in gliomas and the correlation between MED8 and tumor immune features and the response to immunotherapy in gliomas. The expression of MED8 in cell lines was studied by qPCR.

Results

Studies show increased expression of MED8 is associated with poor prognosis in glioma. Cox regression analysis and survival analysis revealed that MED8 is an independent prognostic factor in gliomas, and patients with high expression of MED8 have a poor prognosis. Functional analysis revealed that there was a close relationship between MED8 expression and tumor immune features, and there was a correlation between MED8 expression and tumor-associated macrophages (TAMs) levels. In addition, glioma patients with low expression of MED8 were more sensitive to anti-PD-1/anti-CTLA4 immunotherapy, while patients with high expression of MED8 were more sensitive to temozolomide (TMZ).

Conclusion

These results show that MED8 is a marker of prognosis and immunotherapy/chemotherapy response in glioma and a target of anti-TAMs immunotherapy for glioma.